Greenwich LifeSciences Inc. reported that the FLAMINGO-01 Phase III trial screening pace has increased over the past six months to about 200 patients per quarter, or more than 800 patients per year across U.S. and EU sites, representing an approximately 33 percent increase from the previously reported annual rate of 600 patients. The company said more than 1,000 patients have been screened to date, and the 250-patient non-HLA-A02 arm is now fully enrolled with all patients receiving GLSI-100. In a preliminary open-label analysis of the non-HLA-A02 arm after completion of the Primary Immunization Series, the company reported an approximately 80 percent reduction in recurrence rate, with immune response and safety trends described as similar to the HLA-A02 arms and the earlier Phase IIb study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greenwich Lifesciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603030600PRIMZONEFULLFEED9664427) on March 03, 2026, and is solely responsible for the information contained therein.